Key Takeaways
- Uzedy Shows Superior Real-World Outcomes: Compared to oral antipsychotics, Uzedy delivers improved relapse prevention, better treatment adherence, and reduced healthcare resource utilization in adults with schizophrenia.
- TEV-'749 Demonstrates Strong Efficacy and Safety: The Phase III SOLARIS trial results reveal significant symptom improvements with no reported cases of post-injection delirium/sedation syndrome, supporting TEV-'749 as a promising long-acting olanzapine treatment.
- High Patient and Provider Satisfaction: Surveys from the SOLARIS trial indicate broad acceptance of TEV-'749’s dosing regimen and administration method, highlighting its potential to address treatment challenges in schizophrenia care.
New data presented at the 2025 Psych Congress Elevate show strong real-world outcomes for Teva’s Uzedy (risperidone) and promising results from the Phase III SOLARIS trial for TEV-'749 (olanzapine), in the treatment of adults with schizophrenia.
What Barriers do People with Schizophrenia Face in Accessing Optimal Treatment?
According to the company, results show that Uzedy led to improved relapse prevention, treatment adherence, and reduced healthcare use compared to oral therapies, while TEV-'749 demonstrated strong efficacy with no reported cases of post-injection delirium/sedation syndrome (PDSS) across 3,487 injections administered as of March 2025.1
“People living with schizophrenia and their caregivers face a number of significant daily challenges, including barriers to optimal treatment,” said Eric Hughes, MD, PhD, EVP, global R&D, chief medical officer, Teva, in a press release.
Real-World Impact of Uzedy on Schizophrenia Management
Teva conducted two retrospective cohort studies of Uzedy analyzing real-world claims data to evaluate clinical outcomes, treatment patterns, and healthcare resource utilization compared to second-generation oral antipsychotics (SGOAs) and oral risperidone. Both groups included 720 patients continuously enrolled in Medicaid, Medicare, or commercial health plans, observed for two years prior to and six months following treatment initiation.
Uzedy demonstrated a 9% relapse rate compared to 15.4% for SGOAs and 16.8% for oral risperidone. Additionally, Uzedy demonstrated a mean time to relapse of 94 days compared to 61 days for SGOAs and 69 days for oral risperidone. In real-world comparisons, 71.3% of patients treated with Uzedy demonstrated good adherence compared to 52.8% in the SGOA group. Further, patients treated with Uzedy had an average hospital stay of eight days compared to 16 days for the SGOA group.1
Key Findings from the SOLARIS Trial for TEV-'749
The multinational, multicenter, randomized, double-blind, parallel-group, placebo-controlled SOLARIS study evaluated the efficacy, safety, and tolerability of TEV-'749 in 675 adult patients. During period 1, which consisted of the first eight weeks of the study, participants were randomly assigned in a 1:1:1 ratio to receive either a low, medium, or high dose of once-monthly subcutaneous TEV-'749 or placebo. From there, patients who completed period 1 were randomly assigned to one of the three TEV-'749 treatment groups for an additional 48 weeks. The primary endpoint of the study was to evaluate the efficacy of the treatment across all three groups.1,2
Results show that in the 318 mg, 425 mg, and 531 mg doses, the study met its primary endpoint, demonstrating statistically significant improvements in schizophrenia symptoms as measured by the Positive and Negative Syndrome Scale compared to placebo at rates of −9.75, −11.27, and −9.76 respectively. The overall safety profile of TEV-'749 was consistent with existing approved versions of olanzapine, and no new safety signals were identified.1
Patient and Provider Satisfaction with TEV-'749
In April, results from a survey of the SOLARIS trial demonstrated strong patient and healthcare provider satisfaction for TEV-'749. Full results indicated that 92% of patients, 87% of nurses, and 72% of physicians were satisfied with TEV-'749’s initiation regimen, dosing schedule, and overall treatment experience. Additionally, 78.6% of patients preferred the subcutaneous injection over the intramuscular option, mainly due to the needle size.2
“For those who struggle adhering to a daily oral regimen, Uzedy may be an appropriate option to help prevent relapse, reduce hospital visits and lower overall costs to the healthcare system,” continued Hughes, in the press release. “With TEV-'749, our latest data demonstrate its potential to fill a critical gap in the current schizophrenia treatment landscape as a long-acting formulation of olanzapine that may effectively address the risk of PDSS.”
References
1. Teva Presents Latest Schizophrenia Portfolio Data Including Real-World Outcomes with UZEDY® (risperidone) Showing Lower Rates of and Longer Time to Relapse Compared to Oral Treatment Options and New Phase 3 SOLARIS Data Showing No Incidence of PDSS with TEV-'749 (olanzapine) to Date. Teva. May 31, 2025. Accessed June 3, 2025. https://www.tevapharm.com/news-and-media/latest-news/teva-presents-latest-schizophrenia-portfolio-data-including-real-world-outcomes-with-uzedy-risperidone/
2. Teva’s Novel Schizophrenia Drug Candidate Demonstrates High Patient, Provider Satisfaction in Phase III Trial Survey. PharmExec. April 4, 2025. Accessed June 3, 2025. https://www.pharmexec.com/view/teva-novel-schizophrenia-patient-provider-satisfaction
